From: Low-dose aspirin and survival from lung cancer: a population-based cohort study
Medication usage after diagnosis | Cancer-specific deaths | All-cause mortality | All patients | Person years | Cancer-specific mortality | All-cause mortality | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unadjusted | P | Adjusteda | P | Unadjusted | P | Adjusteda | P | |||||||||
HR | 95 % CI | HR | 95 % CI | HR | 95 % CI | HR | 95 % CI | |||||||||
Number of patients | [n = 3,635] | [n = 2,791] | [n = 3,635] | [n = 2,791] | ||||||||||||
Aspirin non-user | 1,609 | 1,855 | 2,474 | 4,481 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | ||||
Aspirin userb | 638 | 795 | 1,161 | 2,264 | 0.96 | 0.87, 1.05 | 0.36 | 0.96 | 0.85, 1.09 | 0.55 | 1.00 | 0.92, 1.09 | 0.92 | 0.94 | 0.84, 1.05 | 0.28 |
Aspirin non-user | 1,609 | 1,855 | 2,474 | 4,481 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | ||||
Aspirin user 1 to 11 prescriptionsc | 440 | 521 | 670 | 1,189 | 0.94 | 0.85, 1.04 | 0.25 | 0.95 | 0.83, 1.08 | 0.42 | 0.97 | 0.88, 1.07 | 0.60 | 0.93 | 0.83, 1.05 | 0.24 |
Aspirin user ≥ 12 prescriptionsc | 198 | 274 | 491 | 1,075 | 1.00 | 0.86, 1.17 | 0.96 | 1.01 | 0.84, 1.23 | 0.89 | 1.07 | 0.94, 1.23 | 0.29 | 0.97 | 0.82, 1.14 | 0.69 |
Aspirin non-user | 1,609 | 1,855 | 2,474 | 4,481 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | ||||
Aspirin user 1–365 tabletsc | 353 | 422 | 541 | 926 | 0.91 | 0.81, 1.02 | 0.12 | 0.92 | 0.80, 1.06 | 0.27 | 0.96 | 0.86, 1.07 | 0.44 | 0.92 | 0.81, 1.05 | 0.21 |
Aspirin user ≥366 tabletsc | 285 | 373 | 620 | 1,338 | 1.03 | 0.90, 1.17 | 0.69 | 1.04 | 0.88, 1.23 | 0.67 | 1.07 | 0.95, 1.20 | 0.28 | 0.97 | 0.84, 1.13 | 0.72 |